CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 30 target
Drug / intervention
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05156450
NCT05156450Phase 2Unknown
CompareCT.gov

Phase Ib/II Clinical Study of TQB3616 Capsules in Combination With Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

West China Hospital·interventional·Posted Dec 14, 2021·Updated Dec 14, 2021

In Brief

A Phase 2 clinical trial evaluating TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone for Prostatic Neoplasms, Castration-Resistant and Drug Therapy, Combination. Targeting 30 participants across 1 site.

Detailed Summary

This is a phase Ib/II clinical study of TQB3616 capsules in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer, to determine the dose for further clinical studies and to evaluate the safety and efficacy of this combined therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Neoplasms, Castration-Resistant, Drug Therapy, Combination
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
20222023202420252026
First PostedDec 14, 2021
Enrollment StartJan 1, 2022
Primary CompletionOct 1, 2023
Study CompletionJan 1, 2024
TodayJul 1, 2026
Enrollment to primary: 1.8 yearsPosted 4.5 years ago

Interventions

TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisonedrug

Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.